Genmin Lu

4.7k citations

49 papers · 2.2k · 2 hit papers · h-index 20

Impact in

Internal Medicine top 0.2%
- Venous Thromboembolism Diagnosis and Management
Cardiology and Cardiovascular Medicine top 1%
- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Antiplatelet Therapy and Cardiovascular Diseases

Papers in

Cardiology and Cardiovascular Medicine 33
- Atrial Fibrillation Management and Outcomes 32
- Cardiac electrophysiology and arrhythmias 2
- Cardiac Arrhythmias and Treatments 2
Hematology 14
- Blood Coagulation and Thrombosis Mechanisms 14

Co-authors: Pamela B. Conley (40 shared papers)John T. Curnutte (27 shared papers)Mark Crowther (20 shared papers)Janet M. Leeds (17 shared papers)Stuart J. Connolly (16 shared papers)Janice Castillo (8 shared papers)Stanley J. Hollenbach (9 shared papers)Mark J. Karbarz (7 shared papers)
Journals: Blood (15 papers)Critical Care Medicine (4 papers)Circulation (3 papers)European Heart Journal (3 papers)Blood Advances (3 papers)
Partner nations: United States Canada Netherlands

In The Last Decade

Genmin Lu

48 papers receiving 2.2k citations

Genmin Lu's Hit Papers

align trajectories log scale

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity 2015 · 757 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2015 New England Journal of Medicine
2013 Nature Medicine

Peers

Countries citing papers authored by Genmin Lu

Since Specialization

Citations

This map shows the geographic impact of Genmin Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Genmin Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Genmin Lu more than expected).

Fields of papers citing papers by Genmin Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Genmin Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Genmin Lu. The network helps show where Genmin Lu may publish in the future.

Co-authors

The 25 scholars most cited alongside Genmin Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Genmin Lu Line = papers co-authored together Genmin Lu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 49 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity New England Journal of Medicine ·Deborah Siegal, John T. Curnutte, Stuart J. Connolly, Genmin Lu, Pamela B. Conley, Brian L. Wiens, Vandana Mathur, Janice Castillo, Michele Bronson, Janet M. Leeds, F. Mar, Alex Gold, Mark Crowther Hit paper breakdown →	2015	757
2	A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa Nature Medicine ·Genmin Lu, Francis DeGuzman, Stanley J. Hollenbach, Mark J. Karbarz, Keith Abe, Gail Lee, Peng Luan, Athiwat Hutchaleelaha, Mayuko Inagaki, Pamela B. Conley, David R. Phillips, Uma Sinha Hit paper breakdown →	2013	550
3	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa Inhibitors Blood ·Mark Crowther, M. Manasar.Vandana, Michael Kitt, Genmin Lu, Pamela B. Conley, Stanley Hollenbach, Janice Castillo, Athiwat Hutchaleelaha, Mark J. Karbarz, Joyce Lin, Lee Barron, Sandra R. Russell, Gallia G. Levy, Stuart J. Connolly, John T. Curnutte	2013	101
4	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal of Edoxaban-Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors Blood ·Mark Crowther, Gallia G. Levy, Genmin Lu, Janet M. Leeds, Joyce Lin, Pratikhya Pratikhya, Pamela B. Conley, Stuart J. Connolly, John T. Curnutte	2014	87
5	Formation of Factors IXa and Xa by the Extrinsic Pathway Journal of Biological Chemistry ·Genmin Lu, George Broze, Sriram Krishnaswamy	2004	68
6	Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa Blood Advances ·Deborah Siegal, Genmin Lu, Janet M. Leeds, Mark J. Karbarz, Janice Castillo, Vandana Mathur, Athiwat Hutchaleelaha, Uma Sinha, Michael M. Kitt, Matt McClure, Stanley J. Hollenbach, John T. Curnutte, Pamela B. Conley, Mark Crowther	2017	56
7	Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors Blood Advances ·Manu Thomas Kalathottukaren, A. Louise Creagh, Srinivas Abbina, Genmin Lu, Mark J. Karbarz, Anjali Pandey, Pamela B. Conley, Jayachandran N. Kizhakkedathu, Charles A. Haynes	2018	53
8	An Anticoagulant RNA Aptamer That Inhibits Proteinase-Cofactor Interactions within Prothrombinase Journal of Biological Chemistry ·Sai K. Buddai, Juliana M. Layzer, Genmin Lu, Christopher P. Rusconi, Bruce A. Sullenger, Dougald M. Monroe, Sriram Krishnaswamy	2009	45
9	Recombinant Antidote for Reversal of Anticoagulation by Factor Xa Inhibitors. Blood ·Genmin Lu, Francis DeGuzman, Sanjay Lakhotia, Stanley J. Hollenbach, David R. Phillips, Uma Sinha	2008	38
10	455 Critical Care Medicine ·Mark Crowther, Genmin Lu, Pamela B. Conley, Janet M. Leeds, Janice Castillo, Gallia G. Levy, Stuart J. Connolly, John T. Curnutte	2014	35
11	Abstract 10: Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Pharmacokinetic and Pharmacodynamic Study of PRT064445, a Universal Antidote for Factor Xa Inhibitors Arteriosclerosis Thrombosis and Vascular Biology ·Mark Crowther, Michael Kitt, Matthew W. McClure, Uma Sinha, Genmin Lu, Mark J. Karbarz, Athiwat Hutchaleelaha, Lee Barron, Vandana Mathur, John T. Curnutte	2013	34
12	Preclinical safety and efficacy of andexanet alfa in animal models Journal of Thrombosis and Haemostasis ·Genmin Lu, Stanley J. Hollenbach, Dale C. Baker, Siusze Tan, Athiwat Hutchaleelaha, J T Curnutte, Pamela B. Conley	2017	31
13	Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model PLoS ONE ·Genmin Lu, Polly Pine, Janet M. Leeds, Francis DeGuzman, Pratikhya Pratikhya, Joyce Lin, J Malinowski, Stanley J. Hollenbach, John T. Curnutte, Pamela B. Conley	2018	30
14	A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers Blood Advances ·Genmin Lu, Pamela B. Conley, Janet M. Leeds, Mark J. Karbarz, Gallia G. Levy, Vandana Mathur, Janice Castillo, Mark Crowther, John T. Curnutte	2020	29
15	Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation Research and Practice in Thrombosis and Haemostasis ·Genmin Lu, Joyce Lin, Khanh Bui, John T. Curnutte, Pamela B. Conley	2020	27
16	Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban Thrombosis and Haemostasis ·Alexander P. Benz, Lizhen Xu, John W. Eikelboom, Saskia Middeldorp, Truman J. Milling, Mark Crowther, Patrick Yue, Pamela B. Conley, Genmin Lu, Stuart J. Connolly, (unknown)	2022	26
17	Abstract 14657: Andexanet-alfa and PER977 (Arapazine) Correct Blood Loss in a Rabbit Liver Laceration Model - Only Andexanet Reverses Markers of fXa-mediated Anticoagulation Circulation ·Stanley J. Hollenbach, Genmin Lu, Francis DeGuzman, Siusze Tan, Pratikhya Pratikhya, Anjali Pandey, Pamela B. Conley, John T. Curnutte	2014	24
18	Abstract 18218: In Vitro Characterization of Andexanet Alfa (PRT064445), a Specific fXa Inhibitor Antidote versus Aripazine (PER977), a Non-specific Reversal Agent Circulation ·Genmin Lu, Jayaprakash Kotha, Juan Cardenas, Michael J. Herr, Anjali Pandey, John T. Curnutte, Pamela B. Conley, Lisa K. Jennings	2014	23
19	ANNEXATM-R: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, DEMONSTRATING REVERSAL OF RIVAROXABAN-INDUCED ANTICOAGULATION IN OLDER SUBJECTS BY ANDEXANET ALFA (PRT064445), A UNIVERSAL ANTIDOTE FOR FACTOR XA (FXA) INHIBITORS Journal of the American College of Cardiology ·Alexander Michael Gold, Mark Crowther, Gallia G. Levy, Genmin Lu, Janet M. Leeds, Lee Barron, Pamela B. Conley, Janice Castillo, John T. Curnutte, Stuart J. Connolly	2015	23
20	PRT064445 but Not Recombinant Fviia Reverses Rivaroxaban Induced Anticoagulation As Measured by Reduction in Blood Loss in a Rabbit Liver Laceration Model Blood ·Stanley J. Hollenbach, Genmin Lu, Siusze Tan, Gail Lee, Athiwat Hutchaleelaha, Mayuko Inagaki, Uma Sinha	2012	19

About Genmin Lu

Genmin Lu is a scholar working on Cardiology and Cardiovascular Medicine, Hematology, Internal Medicine, Molecular Biology and Surgery, having authored 49 papers that have together received 2.2k indexed citations. Recurring topics across this work include Atrial Fibrillation Management and Outcomes (32 papers), Blood Coagulation and Thrombosis Mechanisms (14 papers), Venous Thromboembolism Diagnosis and Management (11 papers), Vitamin K Research Studies (2 papers), Cardiac electrophysiology and arrhythmias (2 papers), Cardiac Arrhythmias and Treatments (2 papers), Case Reports on Hematomas (2 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (2 papers). The work is most often cited by research in Internal Medicine (1.1k citations), Cardiology and Cardiovascular Medicine (1.6k citations), Hematology (332 citations), Critical Care and Intensive Care Medicine (74 citations) and Neurology (134 citations). Genmin Lu has collaborated with scholars based in United States, Canada and Netherlands. Frequent co-authors include Pamela B. Conley, John T. Curnutte, Mark Crowther, Janet M. Leeds, Stuart J. Connolly, Janice Castillo, Stanley J. Hollenbach, Mark J. Karbarz, Vandana Mathur and Athiwat Hutchaleelaha. Their work appears in journals such as Blood, Critical Care Medicine, Circulation, European Heart Journal and Blood Advances.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Genmin Lu

Impact in

Papers in i

In The Last Decade

Genmin Lu

Genmin Lu's Hit Papers

Peers

Countries citing papers authored by Genmin Lu

Fields of papers citing papers by Genmin Lu

All Works

About Genmin Lu

Explore authors with similar magnitude of impact

Papers in